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Background and purpose: The epidermal growth factor receptor (EGFR) is overexpressed or mutated in
many tumour types. The truncated, constitutively active EGFRvIII variant has not been detected in normal
tissues but is found in many malignancies. In the current study, we have investigated the hypothesis that
EGFRvIII contributes to a growth and survival advantage under tumour microenvironment-related stress
conditions.
Materials and methods: U373MG doxycycline-regulated isogenic cells expressing EGFRwt or EGFRvIII
were created and validated using Western blot, FACS and qRT-PCR. In vitro proliferation was evaluated
with standard growth assays. Cell survival was assayed using clonogenic survival. Animal experiments
were performed using NMRI-nu-xenografted mice.
Results: Inducible isogenic cell lines were created and showed high induction of EGFRwt and EGFRvIII
upon doxycycline addition. Overexpression of EGFRvIII but not of EGFRwt in this model resulted in a
growth and survival advantage upon different tumour microenvironment-related stress conditions
in vitro. Induction of EGFRvIII increased tumour growth in vivo, which was reversible upon loss of expres-
sion.
Conclusions: Under conditions where nutrients are limited and stress is apparent, as in the tumour micro-
environment, expression of EGFRvIII leads to a growth and survival advantage. These data indicate a
potential selection of EGFRvIII-expressing tumour cells under such stress conditions.
 2009 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology 92 (2009) 399–404The epidermal growth factor receptor (EGFR) is overexpressed, tant functional changes: the receptor cannot bind ligand, but is
amplified or altered in various human epithelial tumours [1]. Upon
ligand binding and receptor activation, tyrosine residues in their
cytoplasmatic domain are phosphorylated, resulting in the activa-
tion of downstream substrates that control cell proliferation, dif-
ferentiation and survival. It is therefore not surprising that
overexpression of EGFR has been shown to be associated with tu-
mour aggressiveness and treatment resistance [2,3] and that tar-
geting of EGFR is a potentially promising treatment strategy [4–8].
Several reports have documented rearrangements within the
EGFR gene, especially in primary glioblastomas [9]. The most com-
mon variant is EGFRvIII, which harbours an in-frame deletion
resulting in a truncated receptor that lacks 267 amino acids in
the extracellular binding domain. This truncation leads to impor-d Ltd. All rights reserved.
iation Oncology (MAASTRO),
ogy, Uns 50/23, P.O. Box 616,
erlands.
heys).constitutively active, resulting in uncontrolled pro-oncogenic ef-
fects, thereby promoting neoplastic transformation and tumouri-
genicity. The EGFRvIII variant is found in many malignancies,
including breast, head and neck, prostate, lung and brain tumours.
In patients with glioblastoma, the EGFRvIII mutation has an overall
prevalence of 50–60% in patients whose tumours show amplifica-
tion of EGFR [10]. Strikingly, EGFRvIII has not been detected in nor-
mal tissues. Moreover, expression in tumour tissues in vivo is
rapidly lost when cultured in vitro [11]. This observation suggests
that the tumour microenvironment, which is characterized by het-
erogeneities in nutrient supply and oxygenation, may provide suit-
able conditions for growth and survival of EGFRvIII-expressing
tumour cells. The establishment of such a microenvironment, un-
like that of any normal tissue, is a consequence of alterations in
the metabolic and proliferative status of tumour cells together
with a highly irregular vascular supply [12]. This process is be-
lieved to occur early in the development of a tumour, and has been
implicated in promoting metastasis, angiogenesis and increased
malignancy. Cellular adaptive responses to this environment are
400 Influence EGFRvIII on tumour growthcritical for the continued growth of tumours. The role of EGFRvIII
expression in the context of the tumour microenvironment has
only been minimally defined. The present study was performed
to investigate the contribution of EGFRvIII expression on tumour
growth, as well as its importance in determining the response to
microenvironmental stress.
Materials and methods
Plasmids and generation of cell lines
The glioblastoma cell line U373MG (ATCC, Manassas, VA, USA)
was cultured in MEMa medium, supplemented with 10% FBS. Iso-
genic cell lines that can be induced to express either EGFR wild-
type (wt) or EGFRvIII were generated using the Flp-In T-Rex Core
Kit from Invitrogen (Breda, NL), according to the manufacturer’s
recommendations. These cell lines were designated U373FlpIn/
EGFRvIII and U373FlpIn/EGFRwt, respectively. To induce gene
expression, doxycycline (1 lg/ml) was added to the medium.
Antibodies and Western blotting
Western blotting was done according to standard protocols as
described [13]. Antibodies used were Sc-03 (Santa Cruz Biotechnol-
ogy, Huissen, NL) for EGFRwt, L8A4 (a gift from D. Bigner, Duke
University, Durham, NC, USA) for EGFRvIII and HRP-linked anti-
rabbit (EGFRwt) or anti-mouse (EGFRvIII) secondary antibodies.
Immobilized proteins were detected using ECL-plus reagent (Kirk-
egaard & Perry Laboratories, NL) and by exposing blots to X-ray
film.
Quantitative real-time PCR
RNA extraction was performed using the SV Total RNA Isolation
System (Promega Corporation, Madison, WI, USA). cDNA was pre-
pared using the iScript cDNA Synthesis kit (BioRad Laboratories,
CA, USA). Reactions were carried out in a 25 ll volume using SYBR
Green Master Mix (Applied Biosystems, CA) with the ABI Prism
7700 Sequence Detection System. Values for each gene were nor-




EGFRwt forward: 50ACCTGCGTGAAGAAGTGTCC30; and
EGFRwt reverse: 50CCGTCTTCCTCCATCTCATAGC30.
Flow cytometric analysis
FACS analysis with Oregon Green-labeled cetuximab was per-
formed as described [14].
In vitro growth and survival assays
For growth under control aerobic conditions, 2.5  105 cells
were seeded and incubated in 5% CO2 for 1–7 days. To monitor
growth under stress conditions, cells were seeded and allowed to
attach during overnight incubation in 5% CO2. The following day
(day 0), dishes were placed in the hypoxic chamber or medium
was replaced according to the appropriate conditions. Total cell
numbers were counted after trypsinization using a Coulter Z series
particle counter (Beckman, Mijdrecht, NL) and cell numbers nor-
malized to the amount of cells present at day 0. Clonogenic assays
were performed as previously described [13].Tumour xenograft model
In vivo experiments were performed using adult NMRI-nu (nu/
nu) female mice. Animal facilities and experiments were in accor-
dance with local institutional guidelines. U373 FlpIn/EGFRvIII cells
were mixed with matrigel and 3  106 cells were subcutaneously
injected in the lateral flank. Induction of gene expression was done
by giving animals doxycycline (2 g/l) in their drinking water. Tu-
mours were measured with calipers in 3 orthogonal diameters
and volumes calculated with the formula A  B  C  p/6. The tu-
mour doubling time (Td) was calculated using the equation
Td = (T  T0)  log 2/[log(V)  log(V0)] where T  T0 indicates the
length of time between two measurements and V0 and V denote
the tumour volume at two points of measurement.
Statistics
Statistical analysis was carried out using the program GraphPad
Prism version 5.01 for Windows (GraphPad Software, 2007, CA,
USA). A Mann–Whitney U test was used to assess differences in tu-
mour doubling times. Non-linear regression analysis was per-
formed to compare differences between in vivo growth curves.
Student’s t-test was applied to determine differences in growth
and survival assays.
Results
To investigate the potential influence of EGFRvIII on tumour
phenotype, and to compare the effect of EGFRvIII overexpression
with that of EGFRwt, we created doxycycline-inducible U373MG
glioma isogenic cell lines expressing EGFRvIII or EGFRwt. The
unmodified parental U373MG cells express moderate levels of
endogenous EGFRwt and have been widely recognized as a valu-
able in vitro and xenograft model. Previously, we constructed a
Flp-In T-Rex host acceptor cell line, designated U373FlpIn. Follow-
ing transfection and selection, we identified clones for both EGFR-
vIII and EGFRwt. Quantitative PCR revealed induction of mRNA
levels of 7.15 ± 0.6 for EGFRvIII and 7.55 ± 0.6 for the EGFRwt in re-
sponse to doxycycline (Fig. 1A). As shown in Fig. 1B, protein levels
of EGFRvIII were strongly induced after exposure to doxycycline,
with virtually undetectable background levels. EGFRwt is also in-
duced in the U373FlpIn/EGFRwt cells, but to a lesser extent than
EGFRvIII in the U373FlpIn/EGFRvIII cells, presumably due to the al-
ready expressed endogenous EGFRwt levels in U373FlpIn. To show
that the vIII mutant and the wt receptor were properly processed
and located at the cell membrane after doxycycline administration,
we performed a flow cytometry experiment using Oregon Green-
labeled cetuximab (C225-OG) (Fig. 1C). Without doxycycline
induction, both cell lines showed similar levels of C225-OG bind-
ing, indicating binding of C225-OG to endogenous EGFRwt recep-
tor. Increased C225-OG binding was observed when doxycycline
was added, reaching a 5- to 6-fold increase at 72 h. Taken together,
these data demonstrate that the use of this inducible system is fea-
sible and that it results in an increase of correctly processed recep-
tors at the membrane of induced U373FlpIn cells.
To assess the biological relevance of EGFRvIII expression in rela-
tion to stress typically found in the tumour microenvironment, we
evaluated the growth of U373FlpIn/EGFRvIII and U373FlpIn/
EGFRwt inducible isogenic cell lines under conditions of serum
starvation, low pH, glucose deprivation, hypoxia (0.2%) and anoxia.
As shown in Fig. 2, no effect on growth after induction of EGFRvIII
or EGFRwt was observed in medium containing 10% FBS. However,
in conditions of serum starvation, addition of doxycycline to over-
express EGFRvIII resulted in a consistent growth advantage over
non-induced cells (Fig. 2A). In contrast, no proliferation effect
Fig. 1. Validation of U373FlpIn/EGFRvIII and U373FlpIn/EGFRwt doxycycline-inducible isogenic cell line. (A) EGFRvIII and EGFRwt transcript levels in U373FlpIn transfected
cells following addition of doxycycline for 24–72 h, reported as mean ± SEM of triplicate measurements. (B) Representative Western blots showing EGFRvIII and EGFRwt
protein levels after doxycycline induction for 48 h. (C) FACS analysis of C225-OG binding to U373FlpIn/EGFRvIII and U373FlpIn/EGFRwt cells after 24–72 h induction with
doxycycline.
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(Fig. 2B). Similarly, overexpression of EGFRvIII resulted in signifi-
cant induction of proliferation in conditions of low oxygen (0.2%)
(Fig. 2A, p < 0.05) and complete anoxia (Fig. 2A, p < 0.05 at 48 h).
Overexpression of EGFRwt did not lead to increased proliferation
in either hypoxic or anoxic conditions (Fig. 2B), and remained at
the same levels as the non-induced cells. No EGFRvIII-mediated
growth promoting effect could be detected when cells were ex-
posed to low glucose concentrations or when grown at pH 6.2 (data
not shown).
To further address the biological significance of EGFRvIII over-
expression, we performed cell survival assays. In conditions with
low serum concentration, EGFRvIII-expressing cells survived sig-
nificantly better as cells without EGFRvIII (p < 0.01 at 2% and
p < 0.05 at 1%, Fig. 3A). We have previously demonstrated that
EGFRvIII expression promotes hypoxia tolerance [13]. However,
those experiments were performed using cells that stably ex-pressed very high levels of EGFRvIII. We therefore also compared
the hypoxia tolerance of the U373FlpIn/EGFRvIII and U373FlpIn/
EGFRwt cell lines following exposure to 48 h of hypoxia or anoxia.
As shown in Fig. 3A, cells expressing EGFRvIII tolerated hypoxia
(p < 0.05) and anoxia (p < 0.05) better than the cells that did not ex-
press the mutant receptor. Similar to our observations in prolifer-
ation experiments, overexpression of EGFRwt did not increase
hypoxia or anoxia tolerance (Fig. 3B).
To investigate the influence of EGFRvIII expression on tumour
growth in vivo, and to evaluate whether the observed in vitro
observations could be translated to an effect in vivo, we injected
U373FlpIn/EGFRvIII cells in NMRI-mice to form tumours. Mice
were divided in two equal groups (n = 14) of which one received
doxycycline. Cells in both groups formed tumours with similar effi-
ciency and palpable tumours became visible at 12 days post-
injection. As illustrated in Fig. 4A, the tumours in animals that
were given doxycycline grew significantly (p < 0.001) faster as
Fig. 2. EGFRvIII expression results in a growth advantage in tumour microenvironment-related stress conditions. Growth was evaluated by counting cells at the indicated
time points and normalized towards the number of cells present at day 0. Experiments were done in triplicate. Data points represent the mean ± SEM. U373FlpIn/EGFRvIII
cells (A) and U373FlpIn/EGFRwt cells (B) were grown in the absence (dashed line) or presence (full line) of doxycycline at 10% or 0% serum, 0.2% hypoxia or in anoxia.
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by the shorter doubling time of doxycycline-induced tumours ver-
sus the non-induced xenografts (9.3 days versus 10.7 days,
p < 0.05) (Fig. 4B). When tumours reached volumes of 250–
400 mm3, animals from both groups (n = 6) were randomly
switched to the other treatment group by withdrawing or admin-
istering doxycycline. Intriguingly, the tumour growth rate in ani-mals that were switched from no doxycycline to receiving
doxycycline increased and their doubling time, calculated from
the switch onwards, decreased (mean Td = 9.5 days) to levels sim-
ilar to that of tumours in which EGFRvIII was already expressed
from the start of the experiment. Conversely, tumour growth rate
in animals that were taken off doxycycline decreased, and doubling
times (mean Td = 11.7 days) became similar to those of tumours
Fig. 3. EGFRvIII expression influences cell survival in tumour microenvironment-related stress conditions. Clonogenic survival assay of U373FlpIn/EGFRvIII (A) and
U373FlpIn/EGFRwt (B) after exposure to different concentrations of serum, to 0.2% hypoxia or to anoxia for 48 h with (black bars) or without (grey bars) induction with
doxycycline. The mean values of three independent experiments are shown. Error bars represent SEM. (*p < 0.05; **p < 0.01).
J. Theys et al. / Radiotherapy and Oncology 92 (2009) 399–404 403that had never been induced with doxycycline (Fig. 4C). These data
indicate that EGFRvIII promotes the growth of established
tumours.
Discussion
In this study, we have shown that overexpression of EGFRvIII,
but not of EGFRwt, results in a consistent proliferative and survival
advantage when cells were grown under low serum, hypoxia or an-
oxia. Interestingly, the observed in vitro effects were also trans-
lated in increased rates of tumour growth in vivo. Previous
reports have demonstrated a prominent role for EGFRvIII driving
the progression of neoplastic events [15,16]. However, these stud-
ies have been mainly carried out using tumour models that mas-
sively and stably overexpress the mutant receptor. To rule out
clonal effects of stable transfectants and to specifically investigate
the tumourigenic role of EGFRvIII, we therefore developed an iso-
genic inducible system. Because several different transgenes can
be inserted in an identical way into the same parental cell line, it
is possible to compare their contribution and effectiveness in ex-
actly the same genetic background, overcoming a general disad-
vantage of models used until now. Moreover, because EGFRvIII is
constitutively active, an inducible model is particularly useful for
studying such a mutant. Strikingly, whereas expression of the
EGFRvIII-mutant confers proliferation and survival advantages in
conditions of low serum and oxygen availability, overexpression
of the wt receptor did not. This might be explained by the endog-
enous levels of wt receptor that are already present on these cells
(Fig. 1C), masking the effects of a further increase of receptor
expression. However, other mechanisms may explain the differen-
tial phenotypic effect we observed. EGFRvIII has been shown to be
increasingly associated with the adapter proteins Shc and Grb2,
and increased levels of the active form of Ras [17]. A recent
large-scale analysis of phosphorylated proteins induced by EGFR-
vIII expression pointed towards PI3K signaling as the dominantpathway in glioblastoma cells [18]. The significance of this path-
way has also been confirmed in other studies [19,20]. In a differen-
tial gene expression analysis, Ramnarain et al. revealed that
expression of EGFRvIII resulted in specific upregulation of a small
group of genes that are not induced by the wt receptor. These
genes influence signaling pathways known to play a key role in
oncogenesis and function in interconnected networks. Importantly,
EGFRvIII but not EGFRwt plays an important role in generating an
autocrine loop in glioma cells by increasing expression of ligands
for the wt receptor [21]. The signaling potency of EGFRvIII might
also be increased by its ability to signal for a prolonged time as a
result of impaired endocytosis, inefficient ubiquitination and rapid
recycling [22,23]. EGFRwt has been shown to be translationally
upregulated under hypoxia [24]. In the stress conditions we have
tested, however, this did not translate into a measurable pheno-
typic effect. Interestingly, we also observed an increase in EGFRvIII
expression under hypoxia (unpublished observations). Although
the underlying mechanism for the increased EGFRvIII levels is
not yet clear, our data presented here suggest that this induction
may contribute to the observed proliferative and survival advan-
tage. In addition, this might lead to a selection of EGFRvIII-express-
ing cells in vivo, thereby contributing to the aggressive tumour
phenotype. Interestingly, with the inducible model we have devel-
oped, tumours can be established with a parental genotype and
subsequently induced to express a gene of interest to selectively
examine its effect. The fact that tumours start to grow faster as
soon as they are induced to express EGFRvIII (Fig. 4C), underscores
the important role of EGFRvIII in the tumourigenesis process. Con-
versely, we also demonstrate that the increased growth rate of
EGFRvIII-expressing tumours can be reversed when the mutant
receptor is no longer expressed. These data indicate that targeting
EGFRvIII by silencing its expression and/or blocking its down-
stream effects [25], even when EGFRwt receptor levels are rela-
tively high as in our model, might be a promising strategy for
treating cancers that contain this mutated receptor.
Fig. 4. Induction of EGFRvIII increases tumour growth in vivo. (A) U373FlpIn/
EGFRvIII xenografts were established in nude mice (n = 28). Mice were separated in
two groups of which one group (n = 14) received doxycycline (j) and the other
group (n = 14) did not (d). Mean tumour volumes ± SEM are shown. Volumes were
normalized to the start of the measurements (day 0). Data were fitted using an
exponential growth equation. Non-linear regression analysis was subsequently
performed to compare whether both these fits are significantly different (F-test). (B)
Doubling times for tumours growing in animals that received doxycycline (left
panel) or did not receive doxycycline (right panel) (*p < 0.05). (C) Tumour doubling
times in animals after switching of animals of both groups (n = 6) to the other
treatment group by withdrawing or administering doxycycline (*p < 0.05).
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